Why Are These Five Stocks in the Spotlight?

Page 2 of 2

Endo to Consider Asset Sales

According to ReutersEndo International plc – Ordinary Shares (NASDAQ:ENDP) has talked with various PE firms about asset sales to help cut the company’s $8 billion plus debt burden. Endo shares have struggled this year as traders have cooled on acquisition style pharma companies with substantial debt burdens. Shares have also been hurt due to the company’s guidance cut in May. Although Endo has talked with PE firms, there is no guarantee of a deal however. Among the funds we track, 49 funds had a bullish position in Endo International plc – Ordinary Shares (NASDAQ:ENDP) at the end of the first quarter.

Follow Endo Health Solutions Inc. (NASDAQ:ENDP)

Teva Nearing More Divestments

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)‘s planned mega-merger with Allergan’s generic segment is moving closer to the finish line after Teva agreed to sell the rights to another set of generic drugs to Mayne Pharma Group for $652 million. The sold drug portfolio is expected to bring in as much as $237 million in revenue in fiscal year 2017. Teva is divesting some of its generic product lines to win antitrust approval from various governments around the world. A total of 70 funds from our database were long Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) at the end of the first quarter, down by 11 funds from the previous quarter.

Follow Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Disclosure: None


Page 2 of 2